Activated protein C for severe sepsis: review

Sadaka et al add their two cents and a cohort study to the Xigris efficacy/safety debate. In their retrospective, propensity-matched analysis of 563 patients sourced from the Project IMPACT database, the 108 who received activated protein C had 35% mortality, vs 54% for the 108 who did not (p=0.005). There were unusually low rates of bleeding (2.8% GI bleeding in APC group, no brain hemorrhages), compared to previous trials of APC. Authors reported no competing interests. Critical Care 2011;15:R89.

You may also like -

Etomidate associated with increased mortality in sepsis: meta-analysis (Crit Care Med)Xigris X'd! PROWESS-SHOCK negative; activated protein C yanked from global marketContinuing beta blockers safe during acute COPD exacerbations (Thorax)It's the drugs, not the bugs, that determine survival in sepsis (but you already knew that)Occupational organic dusts assoc w. increased lung cancer risk (Thorax)